What is OptimizeRx Corporation's earnings per share (EPS)?

OptimizeRx Corporation (OPRX) reported diluted earnings per share of $0.27 for fiscal year 2025. This represents a 124.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

OptimizeRx Corporation (OPRX) Financials

OPRX

Trailing 12 months to June 30, 2026

Revenue $98.7M -5.8% YoY

Net Income $4.6M +146.6% YoY

EPS (Diluted) $0.23 +142.6% YoY

Free Cash Flow $18.4M +77.5% YoY

Market Cap $137.3M as of Sep 12, 2026

Price / Sales 1.4x on $98.7M revenue, trailing 12 months to June 30, 2026

Price / Earnings 29.8x on $4.6M net income, trailing 12 months to June 30, 2026

Price / Book 1.0x on $131.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OPRX SEC filings page.

OptimizeRx Corporation (OPRX) reported $98.7M in revenue over the twelve months to Jun 30, 2026, down 5.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OPRX FY2025 2026-08-29

Operating turnaround converted revenue scale into cash generation while reducing leverage despite continued interest costs.

Between FY2023 and FY2025, revenue rose from $71.5M to $109.4M, showing that the recovery was accompanied by meaningful commercial expansion. Operating margin moved from -36.9% to 10.7%; cost absorption, not just sales growth, explains why the larger base produced operating profit.

FY2025 operating cash flow was $18.7M against $5.1M of net income, so cash generation exceeded reported profit rather than depending on non-cash earnings. Free cash flow was also $18.7M, with capital expenditures of $58K; reinvestment demand was minimal, leaving little gap between operating cash and free cash flow.

Debt-to-equity fell from 0.3x in FY2023 to 0.2x in FY2025 as long-term debt declined; the financing structure became less debt-dependent. Interest expense was $5.3M against $11.7M of operating income, so financing costs still absorb a sizable share of operating profit even after the turnaround.

Financial Health Signals

Financial Health Score 60/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of OptimizeRx Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

OptimizeRx Corporation held $23.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $18.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and OptimizeRx Corporation scores 85/100 among other emerging companies.

Dilution

OptimizeRx Corporation had 19M shares outstanding at the end of fiscal year 2025, against 18M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and OptimizeRx Corporation scores 66/100 among other emerging companies.

R&D Intensity

OptimizeRx Corporation reported no research and development spending in fiscal year 2025. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and OptimizeRx Corporation scores 1/100 among other emerging companies.

Revenue Progress

OptimizeRx Corporation reported revenue of $109.4M in fiscal year 2025, against $92.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and OptimizeRx Corporation scores 67/100 among other emerging companies.

Burn Trend

OptimizeRx Corporation's operations generated $18.7M of cash in fiscal year 2025, against $4.9M generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and OptimizeRx Corporation scores 98/100 among other emerging companies.

Balance Sheet

OptimizeRx Corporation's cash, cash equivalents and investments came to $23.4M at the end of fiscal year 2025, against $48.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and OptimizeRx Corporation scores 42/100 among other emerging companies.

Altman Z-Score Grey Zone

2.20

OptimizeRx Corporation scores 2.20, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($137.3M) relative to total liabilities ($48.6M). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

8/9

OptimizeRx Corporation passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

3.65x

For every $1 of reported earnings, OptimizeRx Corporation generates $3.65 in operating cash flow ($18.7M OCF vs $5.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

2.21x

OptimizeRx Corporation earns $2.21 in operating income for every $1 of interest expense ($11.7M vs $5.3M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$20.5M

YoY-29.8%

QoQ+3.3%

5Y CAGR+8.5%

10Y CAGR+26.8%

OptimizeRx Corporation generated $20.5M in revenue in Q2 2026. This represents a decrease of 29.8% from the same quarter a year earlier. Against the prior quarter it is up 3.3%.

EBITDA

$976K

YoY-77.2%

QoQ-33.2%

OptimizeRx Corporation's EBITDA was $976K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 77.2% from the same quarter a year earlier. Against the prior quarter it is down 33.2%.

Net Income

-$703K

YoY-145.9%

QoQ-42.0%

OptimizeRx Corporation reported -$703K in net income in Q2 2026. This represents a decrease of 145.9% from the same quarter a year earlier. Against the prior quarter it is down 42.0%.

EPS (Diluted)

-$0.04

YoY-150.0%

QoQ-33.3%

OptimizeRx Corporation earned -$0.04 per diluted share (EPS) in Q2 2026. This represents a decrease of 150.0% from the same quarter a year earlier. Against the prior quarter it is down 33.3%.

Cash & Balance Sheet

Free Cash Flow

$8.6M

YoY+88.4%

QoQ+1857.4%

5Y CAGR+120.1%

10Y CAGR+55.6%

OptimizeRx Corporation generated $8.6M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 88.4% from the same quarter a year earlier. Against the prior quarter it is up 1857.4%.

Cash & Debt

$24.1M

YoY+45.3%

QoQ+19.5%

5Y CAGR-22.1%

10Y CAGR+12.3%

OptimizeRx Corporation held $24.1M in cash against $17.8M in long-term debt as of Q2 2026.

Shares Outstanding

19M

YoY+1.5%

QoQ+0.4%

5Y CAGR+1.3%

10Y CAGR-4.4%

OptimizeRx Corporation had 19M shares outstanding in Q2 2026. This represents an increase of 1.5% from the same quarter a year earlier. Against the prior quarter it is up 0.4%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

76.5%

YoY+12.7pp

QoQ+1.3pp

5Y change+17.5pp

10Y change+24.7pp

OptimizeRx Corporation's gross margin was 76.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 12.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.3 percentage points.

Operating Margin

-0.4%

YoY-11.4pp

QoQ-2.4pp

5Y change-2.9pp

10Y change+31.1pp

OptimizeRx Corporation's operating margin was -0.4% in Q2 2026, reflecting core business profitability. This is down 11.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.4 percentage points.

Net Margin

-3.4%

YoY-8.7pp

QoQ-0.9pp

5Y change-6.0pp

10Y change+27.5pp

OptimizeRx Corporation's net profit margin was -3.4% in Q2 2026, showing the share of revenue converted to profit. This is down 8.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.

Return on Equity

-0.5%

YoY-1.8pp

QoQ-0.2pp

5Y change-0.8pp

10Y change+6.7pp

OptimizeRx Corporation's ROE was -0.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Capital Allocation

R&D Spending

$3.3M

YoY+5.9%

QoQ-3.8%

OptimizeRx Corporation invested $3.3M in research and development in Q2 2026. This represents an increase of 5.9% from the same quarter a year earlier. Against the prior quarter it is down 3.8%.

Capital Expenditures

$35K

YoY+250.0%

QoQ+66.7%

5Y CAGR+8.0%

10Y CAGR+20.8%

OptimizeRx Corporation invested $35K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 250.0% from the same quarter a year earlier. Against the prior quarter it is up 66.7%.

Share Buybacks

Not reported for Q2 2026.

OPRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OPRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$98.7M	$109.4M+18.8%	$92.1M+28.8%	$71.5M+14.5%	$62.5M+1.9%	$61.3M+41.5%	$43.3M+76.1%	$24.6M+16.0%	$21.2M+74.9%	$12.1M+56.5%	$7.8M+7.4%	$7.2M+11.0%	$6.5M+39.0%	$4.7M+135.3%	$2.0M+79.0%	$1.1M
Cost of Revenue	$26.4M	$35.8M+9.4%	$32.7M+14.4%	$28.6M+21.9%	$23.5M-8.5%	$25.7M+33.6%	$19.2M+109.7%	$9.2M+1.8%	$9.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$72.2M	$73.6M+23.9%	$59.4M+38.4%	$42.9M+10.1%	$39.0M+9.3%	$35.6M+47.8%	$24.1M+56.1%	$15.4M+26.5%	$12.2M+105.1%	$6.0M+37.2%	$4.3M+20.6%	$3.6M+9.7%	$3.3M+16.4%	$2.8M+50.4%	$1.9M	N/A
R&D Expenses	N/A	$0	$0	N/A	N/A	N/A	$0-100.0%	$1.6M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	$33.5M+20.9%	$27.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$288K+7.0%	$269K-39.6%	$446K
Operating Income	$10.9M	$11.7M+185.3%	-$13.7M+48.1%	-$26.4M-114.8%	-$12.3M-3503.7%	$361K+116.9%	-$2.1M+42.2%	-$3.7M-2150.5%	$180K+108.5%	-$2.1M-34.7%	-$1.6M-164.7%	-$597K+41.8%	-$1.0M-283.6%	-$268K+41.2%	-$455K+68.7%	-$1.5M
EBITDA	N/A	$16.0M+270.8%	-$9.4M+60.9%	-$24.0M-133.7%	-$10.3M-541.4%	$2.3M+4014.5%	-$59K+97.5%	-$2.4M-585.4%	$497K+127.5%	-$1.8M-34.1%	-$1.3M-411.0%	-$263K+65.4%	-$762K-933.3%	-$74K+72.5%	-$268K+79.5%	-$1.3M
Interest Expense	$4.7M	$5.3M-14.1%	$6.2M+323.7%	$1.5M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$100-100.0%	$959K
Income Tax	$2.1M	$1.8M+150.8%	$725K+109.5%	-$7.6M	N/A	N/A	N/A	-$898K	N/A	N/A	N/A	$0	$0	$0	N/A	N/A
Net Income	$4.6M	$5.1M+125.5%	-$20.1M-14.5%	-$17.6M-53.6%	-$11.4M-3125.4%	$378K+117.1%	-$2.2M+29.8%	-$3.1M-1488.4%	$226K+110.8%	-$2.1M-36.7%	-$1.5M-158.6%	-$595K+42.0%	-$1.0M-283.6%	-$267K+41.2%	-$455K+78.6%	-$2.1M
EPS (Basic)	N/A	$0.28+125.5%	-$1.10-6.8%	-$1.03-60.9%	-$0.64-3300.0%	$0.02+113.3%	-$0.15+34.8%	-$0.23-1250.0%	$0.02+109.5%	-$0.21-320.0%	-$0.05-150.0%	-$0.02+50.0%	-$0.04	N/A	N/A	N/A
EPS (Diluted)	$0.23	$0.27+124.5%	-$1.10-6.8%	-$1.03-60.9%	-$0.64-3300.0%	$0.02+113.3%	-$0.15+34.8%	-$0.23-1250.0%	$0.02	-$0.21	N/A	N/A	N/A	$0.01+133.3%	-$0.03	N/A
Diluted Shares (Avg)	N/A	19M+3.9%	18M+6.8%	17M-3.7%	18M+0.5%	18M+19.3%	15M+10.8%	13M+12.9%	12M	10M	N/A	N/A	24M+13.3%	21M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$20.5M-29.8%	$19.8M-9.5%	$32.2M-0.2%	$26.1M+22.3%	$29.2M+55.2%	$21.9M+11.4%	$32.3M+13.9%	$21.3M+30.5%
Cost of Revenue	$4.8M-54.4%	$4.9M-42.8%	$8.1M-20.9%	$8.6M+8.8%	$10.6M+48.6%	$8.6M+14.7%	$10.3M-2.2%	$7.9M+20.4%
Gross Profit	$15.7M-15.8%	$14.9M+11.9%	$24.1M+9.4%	$17.5M+30.3%	$18.6M+59.2%	$13.3M+9.3%	$22.0M+23.4%	$13.4M+37.2%
R&D Expenses	$3.3M+5.9%	$3.4M+4.6%	N/A	N/A	$3.1M	$3.3M	N/A	N/A
SG&A Expenses	$3.7M-5.3%	$3.5M-22.9%	N/A	$14.4M+7.2%	$3.9M-72.8%	$4.6M-71.8%	N/A	$13.4M+4.2%
Operating Income	-$88K-102.7%	$396K+118.8%	$8.5M+134.9%	$2.0M+123.9%	$3.2M+185.5%	-$2.1M+58.2%	$3.6M+133.2%	-$8.6M-141.0%
EBITDA	$976K-77.2%	$1.5M+244.8%	$9.6M+103.4%	$3.1M+141.9%	$4.3M+260.0%	-$1.0M+74.6%	$4.7M+147.6%	-$7.5M-142.0%
Interest Expense	$1.1M-29.7%	$1.2M-10.9%	$1.2M-20.6%	$1.2M-24.3%	$1.6M+4.9%	$1.3M-16.1%	$1.6M	$1.5M
Income Tax	-$393K-297.5%	-$149K+86.1%	$2.4M+5.9%	$270K+133.0%	$199K+118.3%	-$1.1M-411.9%	$2.3M	-$817K
Net Income	-$703K-145.9%	-$495K+77.5%	$5.0M+6535.9%	$779K+108.5%	$1.5M+138.2%	-$2.2M+68.1%	-$78K+98.1%	-$9.1M-218.5%
EPS (Basic)	-$0.04-150.0%	-$0.03+75.0%	$0.27	$0.04+108.0%	$0.08+136.4%	-$0.12+68.4%	$0.00+100.0%	-$0.50-194.1%
EPS (Diluted)	-$0.04-150.0%	-$0.03+75.0%	$0.26	$0.04+108.0%	$0.08+136.4%	-$0.12+68.4%	$0.00+100.0%	-$0.50-194.1%
Diluted Shares (Avg)	19M-1.2%	19M+1.6%	N/A	19M+6.2%	19M+4.1%	18M+1.7%	N/A	18M+10.1%

OPRX Balance Sheet

OPRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$176.9M+3.4%	$171.2M-6.7%	$183.4M+36.2%	$134.7M-4.5%	$141.0M+133.7%	$60.3M+6.5%	$56.6M+126.1%	$25.1M+156.6%	$9.8M-14.9%	$11.5M-6.8%	$12.3M+75.2%	$7.0M+77.8%	$4.0M+81.7%	$2.2M-24.8%	$2.9M
Current Assets	$64.7M+19.9%	$54.0M-0.7%	$54.3M-44.9%	$98.6M-14.4%	$115.1M+250.3%	$32.9M+21.1%	$27.1M+72.5%	$15.7M+78.6%	$8.8M-13.4%	$10.2M-8.5%	$11.1M+99.5%	$5.6M+111.1%	$2.6M+172.6%	$969K-37.5%	$1.6M
Cash & Equivalents	$23.4M+74.6%	$13.4M-3.4%	$13.9M-23.9%	$18.2M-78.5%	$84.7M+705.2%	$10.5M-44.2%	$18.9M+111.5%	$8.9M+74.0%	$5.1M-27.2%	$7.0M-14.3%	$8.2M+138.1%	$3.4M+208.2%	$1.1M+293.4%	$284K-70.4%	$959K
Short-Term Investments	$0	$0	$0-100.0%	$55.9M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$37.8M-1.2%	$38.2M+5.4%	$36.3M+63.6%	$22.2M-10.7%	$24.8M+38.7%	$17.9M+141.1%	$7.4M+14.9%	$6.5M+88.2%	$3.4M+75.8%	$2.0M-31.5%	$2.8M+35.6%	$2.1M+38.9%	$1.5M	N/A	N/A
Long-Term Investments	$0	$0-100.0%	$568K	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$70.9M0.0%	$70.9M-9.6%	$78.4M+245.6%	$22.7M+53.8%	$14.7M0.0%	$14.7M0.0%	$14.7M+300.7%	$3.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$48.6M-10.2%	$54.2M-4.7%	$56.8M+565.3%	$8.5M-11.1%	$9.6M-7.2%	$10.4M-12.1%	$11.8M+78.5%	$6.6M+86.2%	$3.5M-3.4%	$3.7M+8.7%	$3.4M+39.4%	$2.4M+5.9%	$2.3M+196.5%	$771K-40.9%	$1.3M
Current Liabilities	$21.3M+14.0%	$18.7M+4.3%	$17.9M+113.0%	$8.4M-10.4%	$9.4M-6.6%	$10.0M+64.2%	$6.1M+44.3%	$4.2M+19.4%	$3.5M-3.4%	$3.7M+8.7%	$3.4M+39.4%	$2.4M+5.9%	$2.3M+196.5%	$771K-40.9%	$1.3M
Non-Current Liabilities	$27.4M-23.0%	$35.5M-8.8%	$38.9M+26841.4%	$145K-38.9%	$237K-27.3%	$326K-94.3%	$5.7M+139.7%	$2.4M	$0	$0	$0	$0	$0	$0	$0
Long-Term Debt	$21.4M-30.5%	$30.8M-10.0%	$34.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Total Equity	$128.3M+9.7%	$117.0M-7.6%	$126.6M+0.4%	$126.1M-4.0%	$131.4M+162.9%	$50.0M+11.4%	$44.9M+143.0%	$18.5M+196.7%	$6.2M-20.4%	$7.8M-12.6%	$8.9M+94.0%	$4.6M+176.4%	$1.7M+18.7%	$1.4M-11.6%	$1.6M
Retained Earnings	-$79.2M+6.1%	-$84.4M-31.3%	-$64.3M-37.6%	-$46.7M-32.4%	-$35.3M+1.1%	-$35.6M-6.6%	-$33.4M-10.4%	-$30.3M+0.3%	-$30.4M-7.4%	-$28.3M-5.8%	-$26.7M-2.3%	-$26.1M-4.1%	-$25.1M-1.1%	-$24.8M-1.9%	-$24.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$164.3M-2.9%	$167.3M-0.3%	$176.9M+3.4%	$170.3M+3.1%	$169.3M-2.1%	$167.8M-4.9%	$171.2M-6.7%	$165.2M+33.3%
Current Assets	$54.1M+0.1%	$56.2M+8.6%	$64.7M+19.9%	$56.3M+20.1%	$54.1M+17.6%	$51.7M+6.9%	$54.0M-0.7%	$46.9M-46.3%
Cash & Equivalents	$24.1M+45.3%	$20.2M+21.7%	$23.4M+74.6%	$19.5M+21.0%	$16.6M+10.9%	$16.6M+9.2%	$13.4M-3.4%	$16.1M+62.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%
Accounts Receivable	$24.8M-26.0%	$32.0M-2.2%	$37.8M-1.2%	$32.2M+22.4%	$33.5M+36.7%	$32.7M+10.0%	$38.2M+5.4%	$26.3M+26.3%
Long-Term Investments	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%
Goodwill	$70.9M0.0%	$70.9M0.0%	$70.9M0.0%	$70.9M0.0%	$70.9M-9.6%	$70.9M-9.6%	$70.9M-9.6%	$70.9M+212.6%
Total Liabilities	$33.2M-33.5%	$37.7M-26.9%	$48.6M-10.2%	$48.1M-5.3%	$50.0M-3.6%	$51.5M-4.3%	$54.2M-4.7%	$50.7M+548.6%
Current Liabilities	$9.7M-53.9%	$10.5M-43.0%	$21.3M+14.0%	$18.5M+27.3%	$21.1M+40.8%	$18.4M+9.5%	$18.7M+4.3%	$14.5M+88.3%
Non-Current Liabilities	$23.5M-18.7%	$27.2M-18.0%	$27.4M-23.0%	$29.6M-18.3%	$28.9M-21.6%	$33.1M-10.6%	$35.5M-8.8%	$36.2M+29854.9%
Long-Term Debt	$17.8M-29.3%	$21.3M-26.9%	$21.4M-30.5%	$24.8M-25.5%	$25.1M-22.2%	$29.2M-9.9%	$30.8M-10.0%	$33.3M+573658.6%
Total Equity	$131.1M+9.9%	$129.6M+11.5%	$128.3M+9.7%	$122.3M+6.8%	$119.3M-1.4%	$116.3M-5.1%	$117.0M-7.6%	$114.5M-1.4%
Retained Earnings	-$80.4M+5.4%	-$79.7M+7.9%	-$79.2M+6.1%	-$84.3M0.0%	-$85.0M-13.1%	-$86.6M-21.7%	-$84.4M-31.3%	-$84.3M-40.2%

Not reported in any period shown, so not listed: Inventory.

OPRX Cash Flow Statement

OPRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$18.4M	$18.7M+282.8%	$4.9M+167.5%	-$7.2M-168.0%	$10.7M+1367.4%	$726K+111.5%	-$6.3M-280.0%	-$1.7M-309.5%	$793K+153.6%	-$1.5M-217.6%	-$466K-190.5%	$515K+1014.1%	-$56K-105.0%	$1.1M+281.5%	-$624K-19.7%	-$522K
Depreciation & Amortization	N/A	$4.3M0.0%	$4.3M+80.3%	$2.4M+18.8%	$2.0M+2.9%	$2.0M-5.3%	$2.1M+61.8%	$1.3M+305.3%	$317K-2.5%	$325K+37.9%	$235K-29.5%	$334K+26.3%	$264K+36.4%	$194K+3.6%	$187K+28.8%	$145K
Stock-Based Compensation	N/A	$7.0M-39.3%	$11.5M-16.4%	$13.7M-12.9%	$15.7M+186.7%	$5.5M+73.1%	$3.2M+40.4%	$2.3M-10.3%	$2.5M+2785.1%	$87K-50.1%	$175K-46.6%	$328K-63.6%	$899K+106.5%	$436K+52.5%	$286K	$0
Capital Expenditures	$77K	$58K-48.2%	$112K+28.7%	$87K+7.4%	$81K-19.3%	$100K+47.4%	$68K-22.4%	$88K+155.3%	$34K-18.7%	$42K-76.3%	$178K+8621.1%	$2K-70.7%	$7K	$0-100.0%	$2K-83.0%	$13K
Free Cash Flow	$18.4M	$18.7M+290.6%	$4.8M+165.2%	-$7.3M-169.3%	$10.6M+1589.8%	$626K+109.8%	-$6.4M-264.8%	-$1.7M-330.6%	$758K+149.8%	-$1.5M-136.2%	-$644K-225.6%	$513K+910.1%	-$63K-105.6%	$1.1M+280.9%	-$626K-17.1%	-$535K
Investing Cash Flow	$140K	$68K+115.1%	-$450K+98.2%	-$25.3M+56.4%	-$58.2M-11870.5%	-$486K-289.7%	-$125K+98.8%	-$10.6M-86.1%	-$5.7M-13362.2%	-$42K+87.9%	-$350K-246.2%	-$101K+75.4%	-$410K-37.3%	-$299K-487.1%	-$51K+78.8%	-$240K
Financing Cash Flow	-$11.1M	-$8.8M-79.1%	-$4.9M-117.4%	$28.2M+248.9%	-$19.0M-125.6%	$73.9M+3989.2%	-$1.9M-108.6%	$22.2M+155.4%	$8.7M+2327.1%	-$390K-9.1%	-$357K-108.2%	$4.3M+55.5%	$2.8M	$0	$0-100.0%	$443K
Share Buybacks	N/A	N/A	N/A	$7.5M-62.4%	$20.0M	N/A	N/A	N/A	N/A	$390K-51.7%	$807K	$0-100.0%	$6.0M	$0	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$8.6M+88.8%	-$467K-112.1%	$7.1M+3479.8%	$3.2M+78.8%	$4.6M+483.2%	$3.9M+82.4%	$198K+103.2%	$1.8M+21.6%
Depreciation & Amortization	$1.1M-0.9%	$1.1M-2.7%	$1.1M-1.5%	$1.1M-1.4%	$1.1M+0.1%	$1.1M+2.5%	$1.1M+8.8%	$1.1M+134.5%
Stock-Based Compensation	$2.2M+48.4%	$1.8M+17.3%	N/A	N/A	$1.5M	$1.6M-48.5%	N/A	N/A
Capital Expenditures	$35K+250.0%	$21K-22.2%	$11K-35.3%	$10K-44.4%	$10K-77.8%	$27K-15.6%	$17K+240.0%	$18K-46.2%
Free Cash Flow	$8.6M+88.4%	-$488K-112.7%	$7.1M+3809.9%	$3.2M+80.0%	$4.6M+517.5%	$3.8M+83.9%	$181K+102.9%	$1.8M+23.2%
Investing Cash Flow	-$35K+20.5%	-$21K+75.0%	$206K+271.7%	-$10K+89.1%	-$44K+48.2%	-$84K+45.1%	-$120K+99.5%	-$92K+90.9%
Financing Cash Flow	-$4.7M-3.4%	-$2.7M-361.3%	-$3.4M-22.1%	-$258K+51.5%	-$4.5M-392.3%	-$587K+8.3%	-$2.8M-107.8%	-$532K-52.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

OPRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OPRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	67.3%+2.8pp	64.5%+4.5pp	60.0%-2.4pp	62.4%+4.3pp	58.1%+2.5pp	55.6%-7.1pp	62.8%+5.2pp	57.6%+8.5pp	49.1%-6.9pp	56.0%+6.1pp	49.8%-0.6pp	50.5%-9.8pp	60.2%-34.0pp	94.2%	N/A
Operating Margin	10.7%+25.6pp	-14.9%+22.0pp	-36.9%-17.2pp	-19.7%-20.3pp	0.6%+5.5pp	-4.9%+10.1pp	-15.0%-15.9pp	0.9%+18.4pp	-17.6%+2.8pp	-20.4%-12.1pp	-8.3%+7.5pp	-15.8%-10.1pp	-5.7%+17.1pp	-22.9%	-130.8%
Net Margin	4.7%+26.5pp	-21.8%+2.7pp	-24.6%-6.2pp	-18.3%-18.9pp	0.6%+5.7pp	-5.1%+7.7pp	-12.8%-13.8pp	1.1%+18.4pp	-17.3%+2.5pp	-19.9%-11.6pp	-8.2%+7.5pp	-15.8%-10.1pp	-5.7%+17.1pp	-22.9%	-190.8%
Return on Equity	4.0%+21.2pp	-17.2%-3.3pp	-13.9%-4.8pp	-9.1%-9.4pp	0.3%+4.7pp	-4.4%+2.6pp	-7.0%-8.2pp	1.2%+35.0pp	-33.8%-14.1pp	-19.7%-13.0pp	-6.7%+15.6pp	-22.2%-6.2pp	-16.0%+16.3pp	-32.4%+101.1pp	-133.4%
Return on Assets	2.9%+14.6pp	-11.8%-2.2pp	-9.6%-1.1pp	-8.5%-8.8pp	0.3%+3.9pp	-3.7%+1.9pp	-5.5%-6.5pp	0.9%+22.4pp	-21.6%-8.1pp	-13.4%-8.6pp	-4.8%+9.8pp	-14.6%-7.8pp	-6.8%+14.1pp	-20.9%+52.4pp	-73.3%
Current Ratio	3.04+0.2x	2.89-0.1x	3.04-8.7x	11.74-0.5x	12.29+9.0x	3.28-1.2x	4.44+0.7x	3.72+1.2x	2.49-0.3x	2.78-0.5x	3.30+1.0x	2.31+1.1x	1.16-0.1x	1.26+0.1x	1.19
Debt-to-Equity	0.17-0.1x	0.260.0x	0.27+0.2x	0.070.0x	0.07-0.1x	0.21-0.1x	0.26-0.1x	0.36-0.2x	0.57+0.1x	0.47+0.1x	0.38-0.1x	0.52-0.8x	1.37+0.8x	0.55+0.5x	0.00
Asset Turnover	0.62+0.1x	0.54+0.1x	0.39-0.1x	0.460.0x	0.43-0.3x	0.72+0.3x	0.43-0.4x	0.85-0.4x	1.24+0.6x	0.68+0.1x	0.59-0.3x	0.93-0.3x	1.18+0.3x	0.91+0.5x	0.38
FCF Margin	17.1%+11.9pp	5.2%+15.4pp	-10.2%-27.2pp	16.9%+15.9pp	1.0%+15.7pp	-14.7%-7.6pp	-7.1%-10.7pp	3.6%+16.1pp	-12.6%-4.2pp	-8.3%-15.4pp	7.1%+8.1pp	-1.0%-25.2pp	24.2%+55.7pp	-31.5%+16.6pp	-48.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	76.5%+12.7pp	75.3%+14.4pp	74.8%+6.6pp	67.2%+4.1pp	63.8%+1.6pp	60.9%-1.1pp	68.2%+5.3pp	63.1%+3.1pp
Operating Margin	-0.4%-11.4pp	2.0%+11.6pp	26.5%+15.2pp	7.9%+48.0pp	11.0%+30.9pp	-9.6%+16.0pp	11.3%+49.8pp	-40.2%-18.4pp
Net Margin	-3.4%-8.7pp	-2.5%+7.5pp	15.6%+15.8pp	3.0%+45.8pp	5.3%+26.6pp	-10.0%+25.0pp	-0.2%+14.4pp	-42.8%-25.3pp
Return on Equity	-0.5%-1.8pp	-0.4%+1.5pp	3.9%+4.0pp	0.6%+8.6pp	1.3%+4.6pp	-1.9%+3.7pp	-0.1%+3.2pp	-8.0%-5.5pp
Return on Assets	-0.4%-1.3pp	-0.3%+1.0pp	2.8%+2.9pp	0.5%+6.0pp	0.9%+3.2pp	-1.3%+2.6pp	-0.1%+2.2pp	-5.5%-3.2pp
Current Ratio	5.58+3.0x	5.37+2.6x	3.04+0.2x	3.05-0.2x	2.57-0.5x	2.82-0.1x	2.89-0.1x	3.23-8.1x
Debt-to-Equity	0.14-0.1x	0.16-0.1x	0.17-0.1x	0.20-0.1x	0.21-0.1x	0.250.0x	0.260.0x	0.29+0.3x
Asset Turnover	0.120.0x	0.120.0x	0.180.0x	0.150.0x	0.17+0.1x	0.130.0x	0.190.0x	0.130.0x
FCF Margin	41.8%+26.2pp	-2.5%-20.0pp	21.9%+21.4pp	12.3%+3.9pp	15.6%+11.7pp	17.5%+6.9pp	0.6%+22.6pp	8.3%-0.5pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
OptimizeRx Corporation OPRX	FY2025	$109.4M	$5.1M	4.7%	$137.3M	60/100
Spok Holdings, Inc SPOK	FY2025	$139.7M	$15.9M	11.4%	$222.8M	54/100
TruBridge, Inc. TBRG	FY2025	$346.8M	$4.4M	1.3%	$393.6M	37/100
NRC Health NRC	FY2025	$137.4M	$11.6M	8.4%	$467.2M	50/100
Definitive Healthcare Corp. DH	FY2025	$241.5M	-$138.9M	-57.5%	$112.1M	40/100
So-Young International Inc. SY	FY2025	$217.8M	-$34.6M	-15.9%	$272.7M	33/100

Where OptimizeRx Corporation Ranks

Frequently Asked Questions

What is OptimizeRx Corporation's annual revenue?

OptimizeRx Corporation (OPRX) reported $109.4M in total revenue for fiscal year 2025. This represents a 18.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is OptimizeRx Corporation's revenue growing?

OptimizeRx Corporation (OPRX) revenue grew by 18.8% year-over-year, from $92.1M to $109.4M in fiscal year 2025.

Is OptimizeRx Corporation profitable?

Yes, OptimizeRx Corporation (OPRX) reported a net income of $5.1M in fiscal year 2025, with a net profit margin of 4.7%.

What is OptimizeRx Corporation's EBITDA?

OptimizeRx Corporation (OPRX) had EBITDA of $16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does OptimizeRx Corporation have?

As of fiscal year 2025, OptimizeRx Corporation (OPRX) had $23.4M in cash and equivalents against $21.4M in long-term debt.

What is OptimizeRx Corporation's gross margin?

OptimizeRx Corporation (OPRX) had a gross margin of 67.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is OptimizeRx Corporation's operating margin?

OptimizeRx Corporation (OPRX) had an operating margin of 10.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is OptimizeRx Corporation's net profit margin?

OptimizeRx Corporation (OPRX) had a net profit margin of 4.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is OptimizeRx Corporation's return on equity (ROE)?

OptimizeRx Corporation (OPRX) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is OptimizeRx Corporation's free cash flow?

OptimizeRx Corporation (OPRX) generated $18.7M in free cash flow during fiscal year 2025. This represents a 290.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is OptimizeRx Corporation's operating cash flow?

OptimizeRx Corporation (OPRX) generated $18.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are OptimizeRx Corporation's total assets?

OptimizeRx Corporation (OPRX) had $176.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are OptimizeRx Corporation's capital expenditures?

OptimizeRx Corporation (OPRX) invested $58K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does OptimizeRx Corporation have outstanding?

OptimizeRx Corporation (OPRX) had 19M shares outstanding as of fiscal year 2025.

What is OptimizeRx Corporation's current ratio?

OptimizeRx Corporation (OPRX) had a current ratio of 3.04 as of fiscal year 2025, which is generally considered healthy.

What is OptimizeRx Corporation's debt-to-equity ratio?

OptimizeRx Corporation (OPRX) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is OptimizeRx Corporation's return on assets (ROA)?

OptimizeRx Corporation (OPRX) had a return on assets of 2.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is OptimizeRx Corporation's P/E ratio?

OptimizeRx Corporation (OPRX) trades at 29.8x earnings, its market capitalization divided by net income of $4.6M net income, trailing 12 months to June 30, 2026. The market capitalization is $137.3M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is OptimizeRx Corporation's price-to-sales ratio?

OptimizeRx Corporation (OPRX) trades at 1.4x sales, its market capitalization divided by revenue of $98.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $137.3M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is OptimizeRx Corporation's Altman Z-Score?

OptimizeRx Corporation (OPRX) has an Altman Z-Score of 2.20, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is OptimizeRx Corporation's Piotroski F-Score?

OptimizeRx Corporation (OPRX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are OptimizeRx Corporation's earnings high quality?

OptimizeRx Corporation (OPRX) has an earnings quality ratio of 3.65x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can OptimizeRx Corporation cover its interest payments?

OptimizeRx Corporation (OPRX) has an interest coverage ratio of 2.21x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is OptimizeRx Corporation?

OptimizeRx Corporation (OPRX) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.